The research and development strategy of tibetan new drugs from the perspective of knowledge value chainCHEN Wei-wu, SUN Li-hua2049-2055
The secondary development strategy of Tibetan medicine based on clinical value: taking Qingpeng ointment as an exampleCHEN Wei-wu, SUN Li-hua2056-2062
Research and development of anti-leukemia drugs in China from perspective of patent informationSUN Hui, DONG Li2063-2068
Analysis of the patents of belinostatZHOU Fu-ke, GUO Xiao-yun, CHI Li-na, YUAN Yue, WANG Qin-geng2069-2075
Proficiency-testing of determination for benzyl hydroxybenzoate contentsYANG Rui, XU Kai, WANG Jue, ZHANG Zhao-yang, WANG Lu-lu, ZHAO Xin, LI Hai-liang, SUN Hui-min2076-2080
Effects of ginseng aconite and its effective components combination on the mRNA's expression of oxidase CYP2J3 hydroxylase, CYP4A3 and CYP4F11SUN Jia, ZHANG Guang-ping, SU Ping, MA Meng, CHEN Teng-fei, YANG Yi-fei, HOU Hong-ping, ZHANG Zhong-xiu, GAO Yun-hang, SONG Ling, LI Han, YE Zu-guang2081-2088
Advances in using lipocalin-type prostaglandin D synthase as delivery carrier for poorly water-soluble drugsFAN Lei, TIAN Xia, ZHANG Sheng-nan, MA Shu-li, FAN Yun-zhou2089-2094
Nonclinical efficacy of multiple sclerosis modify drugsSHAN Xiao-lei, WANG Qing-li, HUANG Fang-hua2100-2105
Interpretation of Guidance on CMC Study of Investigational New Chemical Drug Applications for Phase m Clinical Trial任连杰, 周浩辉, 张宁, 霍秀敏2106-2112